Comprehensive chemical characterization of the aerosol generated by a heated tobacco product by untargeted screening

Mark C. Bentley 1 · Martin Almstetter 1 · Daniel Arndt 1 · Arno Knorr 1 · Elyette Martin 1 · Pavel Pospisil 1 · Serge Maeder 1

Received: 23 October 2019 / Revised: 3 February 2020 / Accepted: 7 February 2020 / Published online: 18 February 2020
© The Author(s) 2020

Abstract
A suite of untargeted methods has been applied for the characterization of aerosol from the Tobacco Heating System 2.2 (THS2.2), a heated tobacco product developed by Philip Morris Products S.A. and commercialized under the brand name IQOS®. A total of 529 chemical constituents, excluding water, glycerin, and nicotine, were present in the mainstream aerosol of THS2.2, generated by following the Health Canada intense smoking regimen, at concentrations ≥ 100 ng/item. The majority were present in the particulate phase (n = 402), representing more than 80% of the total mass determined by untargeted screening; a proportion were present in both particulate and gas-vapor phases (39 compounds). The identities for 80% of all chemical constituents (representing > 96% of the total determined mass) were confirmed by the use of authentic analytical reference materials. Despite the uncertainties that are recognized to be associated with aerosol-based untargeted approaches, the reported data remain indicative that the uncharacterized fraction of TPM generated by THS2.2 has been evaluated to the fullest practicable extent. To the best of our knowledge, this work represents the most comprehensive chemical characterization of a heated tobacco aerosol to date.

Keywords Chemical characterization · Untargeted screening · Heated tobacco product · Aerosol · GC×GC-TOFMS · LC-HRAM-MS

Introduction
It is well recognized that cigarette smoking is one of the leading causes of preventable death worldwide [1]. For decades, harm reduction efforts have been focused on preventing smoking initiation and promoting smoking cessation. However, the majority of smoking-related diseases are unrelated to nicotine itself [2] but associated with other toxicants produced from the combustion of tobacco and inhaled by the smoker. In light of this fact, complete cessation of all tobacco and nicotine use should be the ultimate goal for preventing harm from smoking. However, given the number of adult smokers who will continue to smoke cigarettes, estimated at more than 1 billion by 2025, switching to sources of nicotine that do not involve tobacco combustion is seen as an alternative approach to harm reduction, without the need to overcome any addiction to nicotine [3, 4]. To this end, a number of companies, including Philip Morris Products S.A. (PMP), are developing heated tobacco products, which are designed to significantly reduce or eliminate the levels of toxicants found in their aerosol while attempting to preserve the taste, sensory experience, nicotine delivery profile, and ritual characteristics of cigarettes. Such products are intended to meet the requirements of the US Family Smoking Prevention and Tobacco Control Act (FSPTCA, 2009) [5] in order to be defined as modified risk tobacco products (MRTP), thereby allowing their sale or distribution for reducing the harm or risk of tobacco-related diseases associated with commercially marketed tobacco products.

Cigarette smoke is reported to contain more than 6000 chemical constituents [6], which are formed during distillation, pyrolysis, and combustion reactions when tobacco is burned [7]. Various scientific and regulatory bodies have also acknowledged the presence of more than 100 harmful and potentially harmful constituents (HPHC) in tobacco and
cigarette smoke [8–10]. Heated tobacco products are designed to heat tobacco to temperatures below that required to initiate combustion (ca. 400 °C), where an aerosol is generated by the process of evaporation, distillation, and low-temperature pyrolysis of the tobacco substrate, which would include processing agents used during manufacture and any flavor additives, resulting in the production of reduced levels of HPHCs. The Tobacco Heating System 2.2 (THS2.2, commercialized under the brand name IQOS®) is a heated tobacco product developed by PMP, for which the absence of combustion has been confirmed [11]. In order to provide evidence for MRTP classification, PMP uses a structured scientific assessment program that covers both non-clinical and clinical evaluation, which has been applied for assessment of THS2.2 [12]. Part of the non-clinical assessment for THS2.2 involved the targeted measurement of priority toxicants listed by the World Health Organization [13], Health Canada [14], and the US Food and Drug Administration (FDA; reduced panel of 18 constituents) [15], all of which are present in the list of 54 HPHCs routinely measured at PMP for the development of heated tobacco products. Significant reductions have been reported in the levels of all these priority toxicants in the mainstream aerosol of THS2.2 relative to the mainstream smoke of the 3R4F reference cigarette [16], with the majority of HPHC concentrations being comparatively reduced by more than 90% [17].

However, despite these reductions in mainstream aerosol concentrations, and an associated reduction for in vitro toxicity compared with that of 3R4F mainstream smoke [17], there is lingering skepticism within the scientific community as to whether the priority toxicants identified for regulation of cigarettes are directly applicable for assessment of heated tobacco products. Because lower temperatures are used for aerosol formation in such products, where combustion does not occur, the question always arises as to whether a different palate of toxicologically relevant compounds is generated. To generalize, the open question is always “What exactly is in the aerosol?" To answer this question, in this publication, we present the results for the characterization of THS2.2 aerosol using a suite of untargeted analytical methods. To the best of our knowledge, this is the most comprehensive chemical characterization of a heated tobacco aerosol reported to date.

Materials and methods

Approach

In contrast to quantitative analysis, where chemical constituents (analytes) of interest are targeted to the exclusion of all others, an untargeted approach considers indiscriminate determination of all analytes relevant to a specific chemical space. To this end, a portfolio of methods has been developed that aims to deliver maximum coverage for the chemical space related to tobacco-derived aerosols (Fig. 1). These methods are based on comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometry (GC×GC-TOFMS) [18] and liquid chromatography with high-resolution accurate mass spectrometry (LC-HRAM-MS) [19]. They are semi-quantitative in nature, whereby the concentrations of a large number of compounds are estimated versus a limited number of stable isotope-labeled reference standards of known concentrations, using an internal standardization approach. For constituents amenable to gas chromatographic analysis, quantitative values derived from analysis of recognized HPHCs by using targeted methods were compared with corresponding semi-quantified values from untargeted analysis. This demonstrated that, for analytes that were measureable by both techniques, the untargeted approach using GC×GC-TOFMS was able to semi-quantify within a ± 4-fold deviation from the true concentration [18]. Available liquid chromatography–based targeted methods were insufficient to make a similar assessment for LC-HRAM-MS. Therefore, semi-quantification for this approach, as described here, is sufficient to estimate concentrations within a correct order of magnitude. Because the chemical diversity of constituents within a tobacco-derived aerosol is so large, a number of overlapping methods that use both gas and liquid chromatography are required to ensure maximal analytical coverage. However, it should be recognized that not all compounds present will be detected, and, despite the comprehensive nature of this analytical approach, a very small proportion of constituents may be overlooked. For example, mass spectrometers are not able to detect metals in their elemental state or molecules that cannot be electrically charged to create ions.

An untargeted assessment approach is a time-consuming process, especially in the post-analysis data treatment stage, because each chromatographic peak for each individual chemical constituent needs to be evaluated in order to propose a chemical name and provide a semi-quantified concentration. In order to streamline this process, compounds were identified by using software platforms that automated the iterative steps required for accurately identifying each chemical constituent. For GC×GC-TOF methods, an in-house platform was used, which interrogated both commercially available and custom-built [20] mass spectral databases for spectral similarity and compared a number of predicted and measured parameters, such as retention index or relative/absolute retention time in both chromatographic dimensions in order to improve the confidence of identification [21]. For LC-HRAM-MS, a similar workflow was implemented by using the Progenesis QI™ software (Nonlinear Dynamics, Newcastle upon Tyne, UK), which also incorporated a modified MetFrag in silico fragmentation algorithm [22, 23] to enable comparison of experimental and predicted first-order fragmentation spectra.
These methods were applied for analysis of the particulate and gas-vapor phases of aerosols generated by a heated tobacco product and cigarette smoke, represented by THS2.2 and 3R4F, respectively. The aim was to comprehensively characterize the composition of THS2.2 aerosol and provide comparative concentration data for those constituents also confirmed to be present in cigarette smoke.

**Aerosol generation and analysis**

Because data from the different analytical methods were required to be combined, it was essential to ensure comparability between trapping approaches. To this end, a harmonized approach was adopted that employed separate trapping of the particulate and gas-vapor phases (which together comprise whole aerosol or smoke for THS2.2 or 3R4F, respectively), thereby enabling individual chemical characterization of these two distinct phases. Aerosol from THS2.2 and smoke from the reference cigarette 3R4F were generated by using a linear smoking machine in accordance with the Health Canada intense (HCI) smoking regimen [24]. The particulate phase, commonly referred to as total particulate matter (TPM), was collected by passing the smoke/aerosol through a Cambridge (glass fiber) filter pad (CFP), and the gas-vapor phase (GVP) passing through the CFP was trapped by using two micro-impingers in series, which contained solvents maintained at sub-ambient temperatures (Fig. 2). For GC×GC-TOFMS analysis, internal standards for semi-quantification were present within the solvents used to trap the GVP. For LC-HRAM-MS, internal standards were added to samples after the aerosol collection process, but before chromatographic analysis. 3R4F samples were collected as an accumulation of smoke from up to three cigarettes, and for THS2.2, an accumulation of aerosol from up to five heated tobacco “sticks” was collected for analysis. The number of accumulations collected was optimized to match the requirements for individual analytical methods, and replicate sample collection was performed for each required measurement (at least triplicate). The samples were subsequently analyzed by GC×GC-TOFMS [18] and LC-HRAM-MS [19].

For GC×GC-TOFMS, the aerosol or smoke collections (×3 for polar and non-polar methods, ×4 for volatile method) were each injected once for chromatographic analysis. Replicate injections for GC×GC-TOFMS analysis were not performed due to the highly complex nature of the sample extracts, particularly those for the 3R4F reference cigarette, which reduced the effective lifetime of the chromatographic columns used and limited the number of injections that could be made per analytical run. For LC-HRAM-MS, the smoke or aerosol collections (×3) for each method were injected for chromatographic analysis 5 times. The values reported for all methods were the overall mean values for aerosol/smoke collections, and any injection replicates, without the exclusion of any data. Figure 3 presents a graphical representation for the overall variability of the analytical data generated, and shows that more than 80% of the mean values reported had calculated relative standard deviation (RSD) values of less than 30%.
Results

Whole aerosol (TPM and GVP)

Water, nicotine, and glycerin, being highly abundant in THS2.2 aerosol, were determined by using separate quantitative methods and were not considered as part of this untargeted assessment. Excluding these constituents, a total of 529 compounds with concentrations ≥100 ng/item were identified as being present in THS2.2 aerosol by untargeted screening. By applying this nominal reporting threshold of ≥100 ng/item, it was estimated that close to 100% of the total aerosol mass determined by untargeted screening was evaluated [18]. Table 1 presents information on the 100 most abundant compounds present in THS 2.2 aerosol as well as their corresponding concentrations in the smoke of the reference cigarette, 3R4F. A full list of the compounds identified is presented in the ESM.

Three confidence categories were used for structural identification proposals (high, medium, and not identified) based on the combined scores calculated by using mass spectral similarity as well as the comparison of additional predicted and experimental parameters [18, 19]. Once structural proposals were confirmed by comparative analysis using authentic analytical reference standards, the status “confirmed” was assigned to the compounds. During the evaluation of the GC×GC-TOFMS methodology, which was focused upon the smoke of the 3R4F reference cigarette, it was observed that there were higher numbers of reliably identified compounds compared with unidentified compounds where their abundance exceeded 100 ng/item. For compounds of lower abundance, the number of unidentified constituents increased dramatically in comparison with those with reliable proposals, which was most likely attributable to lower spectral quality affecting the identification process. However, other factors may also have contributed, such as the increased presence of less-common structures at lower concentrations that were absent from commercially available mass spectral databases. Focusing on the compounds that were confirmed to be present by reference standard, and also present in commercial mass spectral libraries, the success rate for the GC×GC-TOFMS workflow to propose the true structure as the top “hit” for unknowns classified with “high confidence” (220 compounds) was greater than 90%. For “medium confidence” proposals (17 compounds), this success rate reduced to ca. 75% [18]. For LC-HRAM-MS, the success rate for the workflow to propose the true structure as the top “hit” for unknowns classified with “high confidence” in this investigation was estimated to be lower at 62%. However, this success rate was achieved by inclusion of an in-house experimental mass spectral library in the compound identification workflow. When relying solely on comparisons with mass spectra available in commercially available libraries, this success rate reduced to 14%, primarily due to the fact that the majority of spectra within these libraries are generated using gas chromatography with high energy electron ionization, which are generally not representative of the spectra generated by LC-HRAM-MS ionization processes.
| Compound name                                              | CAS number  | Identification confidence | Aerosol fraction | Conc. in THS2.2 (μg/item) | Conc. in 3R4F (μg/item) |
|------------------------------------------------------------|-------------|---------------------------|------------------|---------------------------|-------------------------|
| 1-Hydroxy-2-propanone/1,2-propenediolk                    | 116-09-6/7333-03-1 | Confirmed TPM              | 1135             | 502                       |
| Acetic acid                                               | 64-19-7     | Confirmed TPM              | 994              | 2659                      |
| Propylene glycol                                          | 57-55-6     | Confirmed TPM              | 643              | 89.6                      |
| 1-Monoacetin                                              | 106-61-6    | Confirmed TPM              | 409              | 434                       |
| Acetaldehyde                                              | 75-07-0     | Confirmed TPM/GVP          | 313              | 1253                      |
| Methanol                                                  | 67-56-1     | Confirmed TPM/GVP          | 211              | 361                       |
| Solanesol                                                 | 13190-97-1  | Confirmed TPM              | 179              | 3382                      |
| Isobutyraldehyde                                          | 78-84-2     | Confirmed GVP              | 116              | 259                       |
| Triacetin                                                 | 102-76-1    | Confirmed TPM              | 112              | 194                       |
| Palmitic acid                                             | 57-10-3     | Confirmed TPM              | 105              | 266                       |
| 3-(2-Hydroxy methoxy)-propane-1,2-diol                    | 14641-24-8  | Confirmed TPM              | 100              | 267                       |
| Cembranoid degradation products (18 compounds)d           | –           | Confirmed TPM              | 93.2             | 193                       |
| Isovaleraldehyde                                          | 590-86-3    | Confirmed TPM/GVP          | 88.7             | 245                       |
| 13,14-Dihydroretinol                                      | 115797-14-3 | Confirmed TPM              | 79.1             | 152                       |
| Linolenic acid                                            | 463-40-1    | Confirmed TPM              | 57.9             | 157                       |
| Propanal                                                  | 123-38-6    | Confirmed GVP              | 57.4             | 386                       |
| 2-Methylbutyaldehyde                                      | 96-17-3     | Confirmed GVP              | 54.7             | 179                       |
| Propanoic acid                                            | 79-09-4     | Confirmed TPM              | 53.2             | 141                       |
| 3-Pyridinol                                               | 109-00-2    | Confirmed TPM              | 52.8             | 218                       |
| β-Nicotyrine                                              | 487-19-4    | Confirmed TPM              | 52.4             | 100                       |
| Pyranone                                                  | 28564-83-2  | Confirmed TPM              | 51.4             | 44.5                      |
| Oleic acid                                                | 112-80-1    | Confirmed TPM              | 50.2             | 107                       |
| Furfural                                                  | 98-01-1     | Confirmed TPM/GVP          | 47.4             | 38.3                      |
| 2-Monoacetin                                              | 100-78-7    | Confirmed GVP              | 46.8             | 30.0                      |
| Linoleic acid                                             | 60-33-3     | Confirmed TPM              | 43.0             | 123                       |
| 2-Furanmethanol                                           | 98-00-0     | Confirmed TPM/GVP          | 37.5             | 9.47                      |
| Acetone                                                   | 67-64-1     | Confirmed GVP              | 34.7             | 268                       |
| 2,3-Butanedione                                           | 431-03-8    | Confirmed TPM/GVP          | 34.0             | 127                       |
| Anhydro sugar derivative                                  | –           | High TPM                   | 30.8             | 43.1                      |
| Octadecanoic acid                                         | 57-11-4     | Confirmed TPM              | 29.4             | 72.7                      |
| 2-Methylfuran                                              | 534-22-5    | Confirmed GVP              | 28.2             | 175                       |
| Furan                                                     | 110-00-9    | Confirmed GVP              | 24.3             | 214                       |
| Neophytiadiene                                            | 504-96-1    | Confirmed TPM              | 23.8             | 43.0                      |
| 1-Linolenoylglycerol                                      | 18465-99-1  | Confirmed TPM              | 23.5             | 42.8                      |
| 5-Hydroxymethylfurfural                                   | 67-47-0     | Confirmed TPM              | 23.0             | 82.1                      |
| α-Levantenolide                                           | 30987-48-5  | Medium TPM                 | 22.8             | 74.8                      |
| 2-Methyl-2-propenal                                       | 78-85-3     | Confirmed TPM/GVP          | 22.0             | 115                       |
| Pentadecanoic acid                                        | 1002-84-2   | Confirmed TPM              | 18.8             | 32.7                      |
| 3-Chloro-1,2-propanediol                                  | 96-24-2     | Confirmed TPM              | 16.1             | 8.21                      |
| 4,6-Dihydroxy-20-nor-2,7-cembradien-12-one                | 119613-98-8 | High TPM                   | 14.6             | 17.8                      |
| 3-Methylpentanoic acid                                    | 105-43-1    | Confirmed TPM              | 14.5             | 12.8                      |
| 5-Methylfurfural                                          | 620-02-0    | Confirmed TPM/GVP          | 14.2             | 5.25                      |
| 1H-Pyrrole                                                | 109-97-7    | Confirmed TPM/GVP          | 14.0             | 24.8                      |
| Phytoene                                                  | 540-04-5    | Medium TPM                 | 13.8             | 247                       |
| Pyridine                                                  | 110-86-1    | Confirmed TPM/GVP          | 13.7             | 68.4                      |
| 6,10,14,18,22,26-Hexamethyl-5,9,13,17,21,25-heptacosahexaen-2-one | 32304-17-9 | Medium TPM                 | 13.2             | 75.3                      |
| Compound name                                      | CAS number | Identification confidence | Aerosol fraction | Conc. in THS2.2 (μg/item) | Conc. in 3R4F (μg/item) |
|---------------------------------------------------|------------|---------------------------|------------------|----------------------------|-------------------------|
| Butanoic acid                                     | 107-92-6   | Confirmed TPM             | 12.7             | 22.4                       |
| 1-Acetyloxy-2-propanone                           | 592-20-1   | Confirmed TPM/GVP         | 12.2             | 9.23                       |
| N-Octanoylnornicotine                             | 38854-10-3 | Confirmed TPM             | 12.1             | 100                        |
| 5,6-Dihydropyridin-2(1H)-one                     | 6052-73-9  | Confirmed TPM             | 11.8             | 38.8                       |
| Methanethiol                                      | 74-93-1    | Confirmed GVP             | 11.7             | 22.9                       |
| Chloromethane                                     | 74-87-3    | Confirmed GVP             | 11.1             | 32.1                       |
| Heptacosane                                       | 593-49-7   | Confirmed TPM             | 10.2             | 8.41                       |
| α-Tocopherolquinone                              | 7559-04-8  | Confirmed TPM/GVP         | 10.0             | 40.5                       |
| 2-Butanone                                        | 78-93-3    | Confirmed GVP             | 10.0             | 128                        |
| 3-Hydroxy-2-butanoxy                              | 513-86-0   | Confirmed TPM/GVP         | 9.43             | 11.2                       |
| Arachidic acid                                    | 506-30-9   | Confirmed TPM             | 8.91             | 35.8                       |
| α-Cembratriene-diol                               | 57605-80-8 | High TPM                   | 8.49             | 0.393                      |
| (9Z,12Z)-18-Hydroxy-9,12-octadecadienoic acid     | 4546-59-2  | High TPM                   | 8.47             | 21.9                       |
| 2-Cyclopentene-1,4-dione                          | 930-60-9   | Confirmed TPM/GVP         | 8.40             | 2.01                       |
| 2-Cyclopenten-1-one                               | 930-30-3   | Confirmed TPM/GVP         | 8.20             | 46.9                       |
| 2H-Pyran-2-one, tetrahydro-5-hydroxy              | 33691-73-5 | Confirmed TPM              | 8.16             | 4.13                       |
| 2-Furalcarboxylic acid, 3-methyl                  | 4412-96-8  | Confirmed TPM              | 8.06             | 18.9                       |
| trans-Crotonaldehyde                              | 123-73-9   | Confirmed TPM/GVP         | 7.87             | 210                        |
| 5-Oxo-1-tetradecyl-3-pyrrolidinecarboxylic acid   | 10054-22-5 | Medium TPM                 | 7.79             | 19.6                       |
| trans-Solanone                                    | 54868-48-3 | Confirmed TPM/GVP         | 7.75             | 12.7                       |
| Palmitoleic acid                                  | 373-49-9   | Confirmed TPM              | 7.46             | 22.0                       |
| Isoraimonol                                       | 82458-63-7 | High TPM                   | 7.42             | 11.4                       |
| Scoopoletin                                       | 92-61-5    | Confirmed TPM/GVP         | 7.21             | 42.3                       |
| Anatabine                                         | 581-49-7   | Confirmed TPM              | 7.15             | 11.8                       |
| Behenic acid                                      | 112-85-6   | Confirmed TPM              | 6.57             | 40.1                       |
| 2,3-Pentanedione                                  | 600-14-6   | Confirmed GVP              | 6.43             | 17.0                       |
| Hexadecanoic acid, ethyl ester                   | 628-97-7   | Confirmed TPM              | 6.43             | <0.100                     |
| 2,5-Dimethylfurane                                | 625-86-5   | Confirmed GVP              | 6.38             | 156                        |
| Dimethyl disulfide                                | 624-92-0   | Confirmed GVP              | 6.34             | 74.1                       |
| 2-Methyl-3-pyridinol                              | 1121-25-1  | Confirmed TPM              | 6.23             | 41.0                       |
| 5-Oxo-1-tetradecyl-3-pyrrolidinecarboxylic acid   | 10054-22-5 | Medium TPM                 | 6.16             | 10.8                       |
| α-Tocopherol                                      | 10191-41-0 | Confirmed TPM/GVP         | 5.80             | 25.4                       |
| 1,2-Benzenediol                                   | 120-80-9   | Confirmed TPM/GVP         | 5.73             | 56.5                       |
| Hydroquinone                                      | 123-31-9   | Confirmed TPM              | 5.71             | 80.6                       |
| 2-Hydroxy-3-oxo-butanal                           | 473-80-3   | High TPM/GVP               | 5.60             | 6.58                       |
| Andrograpanin                                     | 82209-74-3 | Confirmed TPM              | 5.57             | 61.7                       |
| N-Cyclohexylnicotinamide                          | 10354-56-0 | Medium TPM                 | 5.56             | 48.3                       |
| Lignoceric acid                                   | 557-59-5   | Confirmed TPM              | 5.47             | 30.1                       |
| 2(5H)-Furanone                                    | 497-23-4   | Confirmed TPM              | 5.45             | 2.13                       |
| 2-Methylbutanoic acid                             | 116-53-0   | Confirmed TPM              | 5.28             | 8.08                       |
| Isoprene                                          | 78-79-5    | Confirmed GVP              | 5.24             | 49.1                       |
| Acrolein                                          | 107-02-8   | Confirmed GVP              | 5.20             | 463                        |
| 3-Methylbutanoic acid                             | 503-74-2   | Confirmed TPM              | 5.13             | 9.98                       |
| 6-Methyl-3-pyridinol                              | 1121-78-4  | Confirmed TPM/GVP         | 5.10             | 21.3                       |
| 1,4,7,10-Cyclooctadecatetraene, 1,7,11-trimethyl-4(1-methylethenyl) | 101159-07-3 | High TPM/GVP | 4.93 | 11.9 |
| Butyrolactone                                     | 96-48-0    | Confirmed TPM              | 4.80             | 1.08                       |
In this investigation, ca. 67% of the compounds identified by LC-HRAM-MS were confirmed by reference standard, versus ca. 87% for GC×GC-TOFMS, reflective of the lower success rate for compound identification using the LC-HRAM-MS workflow. Overall, 80% of the total number of structural proposals made was confirmed by the use of reference standards. In terms of the total mass characterized, more than 96% was confirmed by reference standards, with only 0.2% of the total mass being assigned as “not identified” (Fig. 4). Compounds identified with either “high” or “medium” confidence are yet to be confirmed by a reference standard, primarily owing to their lack of commercial availability.

Of the 529 compounds, 363 (68.6%) and 127 (24.0%) were exclusively found in the particulate and gas-vapor phases, respectively, and 39 (7.4%) compounds were partitioned between both particulate and gas-vapor phases. The particulate phase represented 81.3% of the total mass determined by untargeted screening. All 529 compounds were also determined to be present in the smoke of the 3R4F reference cigarette, with only a minority of the compounds being present in THS2.2 aerosol at concentrations exceeding those measured in the smoke of the 3R4F reference cigarette. The GVP, which represented just under 20% of the total mass determined by untargeted screening, was represented by 166 compounds. More than 80% of the determined mass for the GVP present in THS2.2 aerosol was contributed by the 14 most abundant chemical constituents, with more than 50% represented by just four constituents (see Fig. 5). It was not possible to compare the analytically determined mass contribution of the gas-vapor phase with any gravimetrically determined value, since it was not feasible to measure the mass of the gas-vapor phase generated using the trapping system, as described. Accordingly, no mass-based estimate for the achieved chemical coverage could be made. The major compound classes contributing to the GVP fraction were aldehydes, ketones, alcohols, and furanic compounds.

### Table 1 (continued)

| Compound name | CAS number | Identification confidence | Aerosol\(b\) fraction | Conc. in THS2.2 (μg/item) | Conc. in 3R4F (μg/item) |
|---------------|------------|---------------------------|------------------------|---------------------------|------------------------|
| Myristic acid | 544-63-8   | Confirmed TPM             | 4.62                   | 18.7                      |
| Stearidonic acid | 20290-75-9 | Confirmed TPM             | 4.56                   | 21.3                      |
| Hentriacontane | 630-04-6   | Confirmed TPM             | 4.54                   | 20.4                      |
| Benzene      | 71-43-2    | Confirmed GVP             | 4.41                   | 106                       |
| Acetamide    | 60-35-5    | Confirmed TPM             | 4.30                   | 38.7                      |
| 3-Methylpalmitic acid | 42172-35-0 | Medium TPM               | 4.27                   | 11.7                      |

*TPM*, total particulate matter; *GVP*, gas-vapor phase
\(b\)Semi-quantified concentration represents the sum value for two tautomers, which interconvert inconsistently during analysis
\(c\)Concentration determined quantitatively
\(d\)Degradation experiments with suspected precursors were performed, which confirmed the compound class proposal
\(e\)CAS number corresponds to one of the isomeric forms for this compound

![Compound Identification Status by Mass](image)

**Fig. 4** Distribution of compound identification status by mass

![GVP Mass versus Number of Compounds](image)

**Fig. 5** Cumulative mass of individual chemical constituents contributing to THS2.2 GVP, ranked in order from the highest (left) to lowest (right) individual mass contribution (GVP, gas-vapor phase)
Nicotine-free dry particulate matter

Cigarette smoke collection by using a CFP is routinely performed to determine nicotine, water, and nicotine-free dry particulate matter (NFDPM) (sometimes referred to as “tar”) concentrations by following a defined smoking regimen such as the HCI regimen [24]. The total mass of collected material (TPM) is obtained by calculating the weight difference of the CFP before and after smoke/aerosol collection. Water and nicotine are extracted from the CFP and quantified. Their masses are then subtracted from the TPM value to obtain the value for NFDPM (NFDPM = TPM − [water + nicotine]). However, it should be recognized that, although it is possible to formally calculate NFDPM values for both heated tobacco products and cigarettes, a direct comparison would be misleading because of the markedly higher proportion of humectants and lower levels of toxics in the NFDPM of heated tobacco products than in cigarettes [25]. In addition, for THS2.2 aerosol, which is primarily composed of water, the standard methodology applied for cigarettes (ISO 4387:2000) [26] was not adequate to fully recover the increased amount of water retained by the CFP, which led to overestimation of NFDPM. An improved method was developed and used internally within PMP for accurately determining TPM delivery and calculating the amount of NFDPM collected [27]. The amount of glycerin collected was also quantitatively determined, since it is a key component of THS2.2 aerosol and is also used in cigarettes as a tobacco humectant.

Figure 6 shows the relative quantities of water, nicotine, and glycerin determined to be present in THS2.2 aerosol by using this improved methodology; here, NFDPM is represented as the sum of masses attributable to glycerin and “others.” The total mass of TPM delivered by THS2.2 aerosol was 56.18 mg/item (determined gravimetrically), with 5.25 mg of the NFDPM portion indicated as being of unknown composition or “others” (i.e., TPM − [water + glycerin + nicotine]). It should be noted that these measurements were performed independently of the smoke/aerosol collections used for untargeted screening, since the extraction method for measuring water, nicotine, and glycerin was not compatible for subsequent untargeted evaluation. Combining the uncertainties for each of the measures required to determine the mass of NFDPM with unknown composition (i.e., TPM, water, nicotine, and glycerin), a 95% confidence interval value of 0.82 should be considered alongside the estimated 5.25 mg amount.

The total mass of NFDPM excluding glycerin (NFDPM-G) estimated by untargeted screening in this investigation was 5.20 mg, with both positive and negative deviations from true concentration, across the full range of compounds identified, assumed to be equivalent. Based upon estimated values, this represented 99% of this previously unknown portion. A total of 402 compounds with concentrations ≥ 100 ng/item were identified as being present in NFDPM-G. Approximately 97.9% (5.09 mg) of NFDPM-G estimated by untargeted screening comprised compounds that were either confirmed by using reference standards (95.4%) or identified with a high degree of confidence (2.5%). More than 80% of the estimated mass for NFDPM-G delivered by THS2.2 aerosol was represented by 34 chemical constituents, with over 50% represented by just the four most abundant constituents (see Fig. 7). Although the uncertainties associated with the experimental measurements made during the course of this investigation should be considered, these data demonstrate the most comprehensive characterization of TPM generated by THS2.2 that is technically achievable.
Discussion

In order to maximize coverage of the chemical space related to heated tobacco aerosol and cigarette smoke, a suite of overlapping analytical methods was used, which was designed to cover the broadest possible range of chemical classes. Since the chemical complexity of a smoke or aerosol matrix is extremely high, sample collection and preparation processes were designed to be quick and simple, in order to minimize the occurrence of methodological artifacts. Of specific note was the approach taken to avoid the use of derivatization reagents for the analysis of polar compounds by GC×GC-TOFMS, where direct injection of aqueous samples onto the chromatographic system was performed. Thereby difficulties associated with the identification of compounds from their corresponding derivatives, due to the absence of corresponding spectra in commercially available databases, and further complicated by the fact that some compounds may derivatize in more than one position, were avoided. Although these methodologies were specifically developed to optimize analytical coverage, it is acknowledged that there will be some compromise associated with the application of non-specific sample collection and preparation processes, and that some classes of chemicals will be less amenable for analysis than others. However, a range of different solvents suited to the different (overlapping) methods have been used in order to minimize any shortfall, and only a small minority of constituents are considered to have been overlooked. For example, highly reactive compounds such as unstable radicals, which require specific analytical techniques for stabilization (or derivatization) prior to analysis, will be very short lived within the collection system. Formaldehyde, a highly reactive carboxyl known to be present in both cigarette smoke and heated tobacco aerosol, was also not detected. Mass spectrometric detection also has some limitations, with an inability to detect compounds below the pre-defined scan range (such as carbon monoxide), metals, inorganic acids, ammonia, and compounds that do not easily ionize. There is also an upper mass range limitation of ca. 800 Daltons for the detection of chemical constituents; however, this was not expected to have had a significant impact since compounds with a high molecular mass were not expected to have transferred substantially into the aerosol of a tobacco heating system that relies on volatility for transfer.

Excluding water, glycerin, and nicotine, 529 chemical constituents were identified as being present in THS2.2 aerosol at concentrations ≥ 100 ng/item. Of these compounds, 80% (representing > 96% of the total mass characterized by untargeted analysis) were confirmed by using authentic reference standard materials. The majority of compounds were present in the particulate phase (402, of which 39 were present in both gas-vapor and particulate phases), representing 81.3% of the total mass determined by untargeted screening. Combining the estimated masses for confirmed compounds and compounds identified with a high degree of confidence, while acknowledging the uncertainties associated with experimental measurements, it is reasonable to conclude that the most comprehensive characterization of TPM generated by THS2.2 that is technically achievable has been accomplished.

Mainstream smoke of the 3R4F reference cigarette was demonstrated to contain all 529 compounds that were present in THS2.2 aerosol (at concentrations ≥ 100 ng/item), and only a minority of compounds in THS2.2 aerosol were present at concentrations exceeding those measured in the smoke of the 3R4F reference cigarette. As such, one may broadly consider the composition of THS2.2 aerosol to be a subset of cigarette smoke, thereby rendering moot any assumption that a completely different palate of toxicologically relevant compounds will be present in the aerosol of heated tobacco products. Of course it is recognized that, with the application of a reporting threshold set at 100 ng/item, the presence of any compounds representing a toxicological concern at concentrations below this threshold would be overlooked. However, in the context of “new hazard” identification, PMP also uses the methods reported in this publication for a differential screening approach, which does not apply a concentration reporting threshold. A previous study, submitted to the FDA within the context of PMP’s MRTP application, was performed using this differential screening approach and the constituents that were found to be significantly higher in THS2.2 aerosol compared with 3R4F smoke, including three compounds that were unique to THS2.2 aerosol (cis-sesquisabine hydrate, 61 ng/item; ethyl dodecanoate, 23 ng/item; and benzenemethanol, 4-hydroxy, 11 ng/item), were submitted for toxicological evaluation [28]. These three compounds unique to THS2.2 aerosol were all found at concentrations below 100 ng/item, demonstrating the ability of the methodology to discriminate differences at concentrations approximating to an order of magnitude lower than the applied 100 ng/item threshold. Four additional compounds, not present within any list of priority toxicants currently used for the regulatory reporting of tobacco products, were subsequently highlighted to be of toxicological concern, namely glycidol, 3-monochloropropane-1,2-diol (3-MCPD), 2-furanmethanol, and furfural [29]. In response to these findings, presented to the FDA in May 2017, as part of PMP’s Premarket Tobacco Product Application (PMTA) for the marketing of IQOS® in the USA, the FDA summarized their review of these toxicological findings with the statement that “Although some of the chemicals are genotoxic or cytotoxic, these chemicals are present in very low levels and potential effects are outweighed by the substantial decrease in the number and levels of HPHCs found in combusted cigarettes” [30]. It is clear that the priority toxicants currently selected for regulatory reporting of tobacco products by different authorities (e.g., FDA reduced list of 18 HPHCs for the USA [15], or Health Canada list of 44 HPHCs for Canada
[15]) remain applicable for the assessment of heated tobacco products. For toxics that have been observed to be increased in, or specific to, heated tobacco products compared with combusted cigarettes, their inclusion in specific lists of HPHCs for such products could be considered. However, the small increase in number for such specific HPHCs should be strongly weighed and evaluated in the context of the overall reduction in the numbers and quantities of chemical constituents, including known HPHCs [17], and additionally assessed using biological assays that evaluate the aerosol as a whole.

To the best of our knowledge, this is the first time that such a comprehensive in-depth chemical characterization of the aerosol composition of a heat-not-burn product has been reported. This work represents several years of effort in the field of analytical method development and advanced structural identification techniques, which have been applied to the aerosol of THS2.2.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. US Department of Health and Human Services. The health consequences of smoking - 50 years of progress: a report of the Surgeon General. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, USA. 2014. https://www.ncbi.nlm.nih.gov/books/NBK179276/pdf/Bookshelf_NBK179276.pdf. Accessed 10 Dec 2019.

2. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362:2295–303.

3. McNeil A. Reducing harm from nicotine use. In: Fifty years since smoking and health. Progress, lessons and priorities for a smoke-free UK. Royal College of Physicians, London. 2012. https://www.rcplondon.ac.uk/sites/default/files/media/Documents/Nicotinewithoutharm.pdf. Accessed 10 Dec 2019.

4. Tobacco Advisory Group. Nicotine without smoke: tobacco harm reduction. Royal College of Physicians, London. 2016. https://www.rcplondon.ac.uk/sites/default/files/media/Documents/Nicotinewithoutharm.pdf. Accessed 10 Dec 2019.

5. United States Family Smoking Prevention and Tobacco Control Act. Public Law No. 111–131. Congress of the Senate and House of Representatives of the United States of America. 2009. https://www.govinfo.gov/content/pkg/PLAW-111publ31/pdf/PLAW-111publ31.pdf. Accessed 01 Dec 2019.

6. Rodgman A, Perfetti TA. The chemical components of tobacco and tobacco smoke. 2nd ed. Boca Raton: CRC Press; 2013.

7. Baker RR. A review of pyrolysis studies to unravel reaction steps in burning tobacco. J Anal Appl Pyrolysis. 1987;11:555–73.

8. Burns DM, Dyinge E, Gray N, Hecht S, Anderson C, Sanner T, et al. Mandated lowering of toxics in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob Control. 2008;17:132–41.

9. U.S. Food and Drug Administration. Harmful and potentially harmful constituents in tobacco products and tobacco smoke. Established list April 2012. Vol 77, No 64, FR 2003-37, Federal Register. https://www.gpo.gov/fdsys/pkg/FR-2012-04-03/pdf/2012-7727.pdf. Accessed 10 Dec 2019.

10. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans - volume 83. Tobacco smoke and involuntary smoking. IARC. Lyon, France; 2004. https://www.ncbi.nlm.nih.gov/books/NBK316407/. Accessed 10 Dec 2019.

11. Cozanni V, Barontini F, McGrath T, Mahler B, Nordlund M, Smith M, et al. An experimental investigation into the operation of an electrically heated tobacco system. Thermochim Acta. 2020. https://doi.org/10.1016/j.tca.2019.178475.

12. Smith MR, Clark B, Lüdicke F, Schaller J-P, Vanscheeuwenjck P, Hoeng J, et al. Evaluation of the Tobacco Heating System 2.2. Part 1: description of the system and the scientific assessment program. Regul Toxicol Pharmacol. 2016;81(Suppl 2):S17–26.

13. World Health Organization. The scientific basis of tobacco product regulation. Report of a WHO study group (TobReg). WHO Technical Report Series 945, Geneva; 2008. https://www.who.int/tobacco/global_interaction/tobreg/who_tsr.pdf. Accessed 10 Dec 2019.

14. Health Canada. Tobacco Reporting Regulations SOR/2000-273, Schedule 2. Government of Canada; 2000. https://laws-lois.justice.gc.ca/PDF/SOR-2000-273.pdf. Accessed 10 Dec 2019.

15. U.S. Food and Drug Administration. Draft guidance for industry: reporting harmful and potentially harmful constituents in tobacco products and tobacco smoke under Section 904(a)(3) of the Federal Food, Drug and Cosmetic Act 1–10. 2012. https://www.fda.gov/media/83375/download. Accessed 10 Dec 2019.

16. University of Kentucky Center for Tobacco Reference Products. 3R4F preliminary analysis. https://ctrp.uky.edu/assets/pdf/webdocs/3R4FPreliminaryAnalysis.pdf. Accessed 10 Dec 2019.

17. Schaller J-P, Keller D, Poget L, Pratte P, Kaelin E, McHugh D, et al. Evaluation of the Tobacco Heating System 2.2. Part 2: chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol. Regul Toxicol Pharmacol. 2016;81(Suppl 2):S27–47.

18. Knorr A, Almstetter M, Martin E, Castellon A, Pospisil P, Bentley M.C. et al. Computer-assisted structure identification (CASI)–an
22. Wolf S, Schmidt S, Muller-Hannemann M, Neumann S. In silico fragmentation for computer assisted identification of metabolite mass spectra. BMC Bioinformatics. 2010;11:148–59.

23. Nonlinear Dynamics web site. Progenesis QI theoretical fragmentation algorithm. http://www.nonlinear.com/progenesis/qi/v2.4/faq/theoretical-fragmentation-algorithm.aspx. Accessed 10 Dec 2019.

24. Health Canada. Determination of “tar”, nicotine and carbon monoxide in mainstream tobacco smoke; Official Method T-115:1999. Government of Canada; 1999.

25. Mallock N, Böss L, Burk K, Danziger M, Welsch T, Hahn H, et al. Levels of selected analytes in the emissions of “heat-not-burn” tobacco products that are relevant to assess human health risks. Arch Toxicol. 2018;92(6):2145–9.

26. International Organization for Standardization. Cigarettes – determination of total and nicotine-free dry particulate matter using a routine analytical smoking machine; ISO Standard 4387:2019; 2019. https://www.iso.org/standard/76549.html.

27. Ghosh D, Jeannet C. An improved Cambridge filter pad extraction methodology to obtain more accurate water and “tar” values: in situ Cambridge filter pad extraction methodology. Beiträge zur Tabakforschung/Contributions to Tobacco Research. 2014;26(2):38–49.

28. Amendment to Philip Morris Products S.A. Modified Risk Tobacco Product Application. Response to 4 Aug 2017 FDA advice and information request letter including non-targeted differential screening, toxicological assessment, and peer review reports. 8 Dec 2017 (MR0000097.zip -20MB; added 12 Jan 2018); Report RLS-ZRH-2016-75 GCxGC-TOFMS.pdf, Report RLS-ZRH-2016-76-82 LC-HRAM-MS.pdf. https://digitalmedia.hhs.gov/tobacco/static/mrtpa/PMP/MR0000097.zip. Accessed 10 Dec 2019.

29. Amendment to Philip Morris Products S.A. Modified Risk Tobacco Product Application. Response to 4 Aug 2017 FDA advice and information request letter including non-targeted differential screening, toxicological assessment, and peer review reports. 8 Dec 2017 (MR0000097.zip -20MB; added 12 Jan 2018); Tox-Ass-Report-NTDS-2017.pdf. https://digitalmedia.hhs.gov/tobacco/static/mrtpa/PMP/MR0000097.zip. Accessed 10 Dec 2019.

30. U.S. Food and Drug Administration. Premarket Tobacco Product Marketing Order TPL (Technical Project Lead Review) PM0000424-79. 29 Apr 2019; Section 6 - Summary of Toxicological Findings:p42. https://www.fda.gov/media/124247/download. Accessed 10 Dec 2019.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.